Download PDF
Thromb Haemost 1999; 82(05): 1528-1531
DOI: 10.1055/s-0037-1614866
Rapid Communications
Schattauer GmbH

Mutations of the Platelet Thromboxane A2 (TXA2) Receptor in Patients Characterized by the Absence of TXA2–induced Platelet Aggregation despite Normal TXA2 Binding Activity

Wataru Higuchi
1   From the First Department of Internal Medicine, Niigata University School of Medicine, Japan
,
Ichiro Fuse
1   From the First Department of Internal Medicine, Niigata University School of Medicine, Japan
,
Akira Hattori
2   Internal Medicine, Sado Kouseiren Hospital, Japan
,
Yoshifusa Aizawa
1   From the First Department of Internal Medicine, Niigata University School of Medicine, Japan
› Author Affiliations
Further Information

Publication History

Received 12 April 1999

Accepted after revision 07 July 1999

Publication Date:
09 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Previously, we reported five cases of platelet dysfunction characterized by the absence of thromboxane A2 (TXA2) – induced platelet aggregation despite normal TXA2 binding activity. In this platelet disorder, patients were divided into two groups; i.e. those whose platelets lacked or did not lack phospholipase C (PLC) activation (Group A and Group B, respectively) (Thromb Haemost 1996; 76: 1080). Furthermore, in one of the patients, we showed that a single amino acid substitution (Arg60 to Leu) in the first cytoplasmic loop of the TXA2 receptor (TXR) was responsible for this platelet disorder. However, mutational analysis of the TXR in the remaining patients has not been performed. Based on this background, we investigated the mutations of the TXR in these patients, and found that all of the patients have the same abnormality of the TXR (Arg60 → Leu), although the Group A patients were homozygous and the Group B patients were heterozygous for this mutation.

This mutation is the only abnormality which has been found in this platelet disorder, and in patients heterozygous for this mutation, the mutant type TXR suppresses wild-type receptor-mediated platelet aggregation by a mechanism independent of PLC activation.

Keywords

Platelet dysfunction - thromboxane A2 - receptor - point mutation
 

  • References

  • 1 Wu KK, Le Breton GC, Tai HH, Chen YC. Abnormal platelet response to thromboxane A2 . J Clin Invest 1981; 67: 1801-4.
    CrossrefPubMedGoogle Scholar
  • 2 Lages B, Malmsten C, Weiss HJ, Samuelsson B. Impaired platelet response to thromboxane A2 and defective calcium mobilization in a patient with a bleeding disorder. Blood 1981; 57: 545-52.
    PubMedGoogle Scholar
  • 3 Samama M, Lecrubier C, Conrad J, Hotchen M, Breton-Gorius J, Vargaftig B, Chignard M, Lagarde M, Dechavanne M. Constitutional thrombocytopathy with subnormal response to thromboxane A2 . Br J Haematol 1981; 48: 293-303.
    CrossrefPubMedGoogle Scholar
  • 4 Hattori A, Takahashi H, Takahashi M, Shibata A, Okuma M. A new familial defect of platelet release mechanism (the intracellular Ca++ transport defect?). Acta Haematol Jpn 1981; 44: 969-72.
    PubMedGoogle Scholar
  • 5 Okuma M, Takahashi H, Uchino H. Subnormal platelet response to thromboxane A2 in a patient with chronic myeloid leukemia. Br J Haematol 1982; 51: 469-77.
    CrossrefPubMedGoogle Scholar
  • 6 Machin SJ, Keenan JP, McVerry BA. Defective platelet aggregation to the calcium ionophore A23187 in a patient with a lifelong bleeding disorder. J Clin Pathol 1983; 36: 1140-4.
    CrossrefPubMedGoogle Scholar
  • 7 Hardisty RM, Machin SJ, Nokes TJC, Rink TJ, Smith SW. A new congenital defect of platelet secretion: impaired responsiveness of platelets to cytoplasmic free calcium. Br J Haematol 1983; 53: 543-57.
    CrossrefPubMedGoogle Scholar
  • 8 Ushikubi F, Okuma M, Kanaji K, Sugiyama T, Ogorochi T, Narumiya S, Uchino H. Hemorrhagic thrombocytopathy with platelet thromboxane A2 receptor abnormality: Defective signal transduction with normal binding activity. Thromb Haemost 1987; 57: 158-64.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Fuse I, Mito M, Hattori A, Higuchi W, Shibata A, Ushikubi F, Okuma M, Yahata K. Defective signal transduction induced by thromboxane A2 in a patient with a mild bleeding disorder: Impaired phospholipase C activation despite normal phospholipase A2 activation. Blood 1993; 81: 994-1000.
    PubMedGoogle Scholar
  • 10 Hirata K, Kakizuka A, Ushikubi F, Fuse I, Okuma M, Narumiya S. Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J Clin Invest 1994; 94: 1662-7.
    CrossrefPubMedGoogle Scholar
  • 11 Fuse I, Hattori A, Mito M, Higuchi W, Yahata K, Shibata A, Aizawa Y. Pathogenetic analysis of five cases with a platelet disorder characterized by the absence of thromboxane A2 (TXA2)-induced platelet aggregation in spite of normal TXA2 binding activity. Thromb Haemost 1996; 76: 1080-5.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Katsura M, Miyamoto N, Hamanaka N, Kondo K, Terada Y, Ohgaki Y, Kawasaki A, Tsuboshima M. In vitro and in vivo effects of new powerful thromboxane antagonists (3-alkylamino pinane derivatives). In: Advances in Prostaglandin, Thromboxane and Leukotriene Research. Samuelsson B, Paoletti R, Ramwell P. eds. New York: Raven Press; 1983: 351-7.
    Google Scholar
  • 13 The Trial to Reduce Alloimmunization to Platelet Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997; 337: 1861-9.
    CrossrefPubMedGoogle Scholar
  • 14 D’Angelo DD, Eubank JJ, Davis MG, Dorn GW. Mutagenic analysis of platelet thromboxane receptor cysteines. Roles in ligand binding and receptor-effector coupling. J Biol Chem 1996; 271: 6233-40.
    CrossrefPubMedGoogle Scholar
  • 15 Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S, Narumiya S. Cloning and expression of cDNA for the human thromboxane A2 receptor. Nature 1991; 349: 617-20.
    CrossrefPubMedGoogle Scholar
  • 16 Dixon RA, Sigal IS, Rands E, Register RB, Candelore MR, Blake AD, Strader CD. Ligand binding to the beta-adrenergic receptor involves its rhodopsin-like core. Nature 1987; 326: 73-7.
    CrossrefPubMedGoogle Scholar
  • 17 Kobilka BK, Kobilka TS, Daniel K, Regan JW, Caron MG, Lefkowitz RJ. Chimeric alpha 2-, beta 2-adrenergic receptors: delineation of domains involved in effector coupling and ligand binding specificity. Science 1988; 240: 1310-6.
    CrossrefPubMedGoogle Scholar
  • 18 Wong SK, Parker EM, Ross EM. Chimeric muscarinic cholinergic: beta-adrenergic receptors that activate Gs in response to muscarinic agonists. J Biol Chem 1990; 265: 6219-24.
    PubMedGoogle Scholar
  • 19 Ohyama K, Yamano Y, Chaki S, Kondo T, Inagami T. Domains for G-protein coupling in angiotensin II receptor type I: studies by site-directed mutagenesis. Biochem Biophys Res Commun 1992; 189: 677-83.
    CrossrefPubMedGoogle Scholar
  • 20 Dorn G. Distinct platelet thromboxane A2/prostaglandin H2 receptor subtypes. A radioligand binding study of human platelets. J Clin Invest 1989; 84: 1883-91.
    CrossrefPubMedGoogle Scholar
  • 21 Takahara K, Murray R, Fitzgerald GA, Fitzgerald DJ. The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. J Biol Chem 1990; 265: 6836-44.
    PubMedGoogle Scholar
  • 22 Nakano T, Terawaki A, Arita H. Signal transduction in collagen-stimulated rat platelets is composed of three stages. J Biochem (Tokyo) 1987; 101: 1169-80.
    CrossrefPubMedGoogle Scholar
  • 23 Armstrong RA, Jones RL, Peesapati V, Will SG, Wilson NH. Competitive antagonism at thromboxane receptors in human platelets. Br J Pharmacol 1985; 84: 595-607.
    CrossrefPubMedGoogle Scholar
  • 24 Hirata T, Ushikubi F, Kakizuka A, Okuma M, Narumiya S. Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest 1996; 97: 949-56.
    CrossrefPubMedGoogle Scholar